BR9712289A - Composições e métodos para o tratamento de infecções virais - Google Patents

Composições e métodos para o tratamento de infecções virais

Info

Publication number
BR9712289A
BR9712289A BR9712289-0A BR9712289A BR9712289A BR 9712289 A BR9712289 A BR 9712289A BR 9712289 A BR9712289 A BR 9712289A BR 9712289 A BR9712289 A BR 9712289A
Authority
BR
Brazil
Prior art keywords
treatment
compositions
methods
virus
viral infections
Prior art date
Application number
BR9712289-0A
Other languages
English (en)
Inventor
Frank B Gelder
Original Assignee
Probe International
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Probe International filed Critical Probe International
Publication of BR9712289A publication Critical patent/BR9712289A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1054—Lentiviridae, e.g. HIV, FIV, SIV gag-pol, e.g. p17, p24
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/5555—Muramyl dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Patente de Invenção <B>"COMPOSIçõES E MéTODOS PARA O TRATAMENTO DE INFECçõES VIRAIS"<D>. Descrevem-se métodos e composições para tratamento, diagnose e prevenção de um vírus, que compreende a administração ao paciente, de anticorpos que reagem com regiões de proteínas virais e resultam na neutralização da capacidade infectiva e inativação dos eventos funcionalmente essenciais no ciclo de vida do vírus. Os anticorpos reconhecem epitopos virais que falham em obter uma resposta imune no homem, quando encontrados através de contaminação ou naturalmente no ambiente. Numa modalidade preferida, a invenção propicia composições e métodos úteis para o tratamento e diagnose de infecções por vírus da imunodeficiência humana (HIV).
BR9712289-0A 1996-10-10 1997-10-10 Composições e métodos para o tratamento de infecções virais BR9712289A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2819496P 1996-10-10 1996-10-10
PCT/US1997/018257 WO1998015658A1 (en) 1996-10-10 1997-10-10 Compositions and methods for treating viral infections

Publications (1)

Publication Number Publication Date
BR9712289A true BR9712289A (pt) 1999-08-31

Family

ID=21842081

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9712289-0A BR9712289A (pt) 1996-10-10 1997-10-10 Composições e métodos para o tratamento de infecções virais

Country Status (12)

Country Link
US (6) US6043347A (pt)
EP (1) EP0939835A4 (pt)
JP (2) JP2001502315A (pt)
KR (2) KR100547049B1 (pt)
CN (1) CN1327896C (pt)
AU (1) AU732809B2 (pt)
BR (1) BR9712289A (pt)
CA (1) CA2268372C (pt)
HK (1) HK1023371A1 (pt)
MX (1) MXPA02010374A (pt)
NZ (1) NZ334941A (pt)
WO (1) WO1998015658A1 (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001502315A (ja) * 1996-10-10 2001-02-20 プローブ・インターナショナル ウイルス感染を処置するための組成物および方法
US7157091B1 (en) * 1999-06-18 2007-01-02 Ludwig Institute For Cancer Research MAGE-A1 peptides presented by HLA class II molecules
US6599441B1 (en) * 2000-07-18 2003-07-29 Emerald Biostructures, Inc. Crystallization solutions
CN1339319A (zh) * 2000-08-18 2002-03-13 清华大学 一种治疗艾滋病的药物及其制备方法
US6987184B2 (en) * 2001-02-15 2006-01-17 Signal Pharmaceuticals, Llc Isothiazoloanthrones, isoxazoloanthrones, isoindolanthrones and derivatives thereof as JNK inhibitors and compositions and methods related
JP2007524609A (ja) * 2003-04-10 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド コンフォメーションに関する変種のプロファイリング、抗体組成物
US7206991B2 (en) * 2003-10-15 2007-04-17 Lsi Logic Corporation Method, apparatus and program for migrating between striped storage and parity striped storage
US7311928B2 (en) * 2003-12-09 2007-12-25 Briant Burke Topical compositions containing tea tree oil for treatment of viral lesions
US7723063B2 (en) * 2004-04-28 2010-05-25 Intrinsic Lifesciences Methods for measuring levels of bioactive human hepcidin
US20060110405A1 (en) * 2004-08-20 2006-05-25 Buckheit Robert W Jr Plasma or serum fraction for treatment and prevention of viral infections and related conditions
MX2007008497A (es) * 2005-01-13 2007-09-14 Novartis Vaccines & Diagnostic Ensayos inmunosorbentes enlazados a enzimas usando reactivos de peptidos especificos de prion.
EP1855112A1 (en) * 2006-05-10 2007-11-14 Inserm Method for the in vitro screening of compounds inhibiting production of infectious HIV-1 virions
US8200520B2 (en) 2007-10-03 2012-06-12 International Business Machines Corporation Methods, systems, and apparatuses for automated confirmations of meetings
BRPI0906312A2 (pt) * 2008-04-01 2016-07-05 Innate Therapeutics Ltd "uso de micropartícula de dpm/dna para a fabricação de composto, composição e vacina"
US9415061B2 (en) * 2008-04-01 2016-08-16 Innate Immunotherapeutics Limited Compositions and methods for treatment of neoplastic disease
NZ571665A (en) 2008-09-30 2011-01-28 Innate Therapeutics Ltd Compositions and methods for treatment of radiation exposure utilising cross-linked muramyl dipeptide microparticles
WO2010134305A1 (ja) 2009-05-18 2010-11-25 国立大学法人東京医科歯科大学 Ｈｉｖ立体構造認識抗体誘導ペプチド抗原、及びその合成方法
NZ577731A (en) * 2009-06-16 2010-08-27 Innate Therapeutics Ltd Compositions and methods for treatment of multiple sclerosis
ES2625406T3 (es) 2010-03-25 2017-07-19 Oregon Health & Science University Glicoproteínas de CMV y vectores recombinantes
RU2517084C2 (ru) * 2010-08-06 2014-05-27 Олег Ильич Эпштейн Способ и средство для ингибирования продукции или усиления элиминации белка р24
CA2832148A1 (en) 2011-04-04 2012-10-11 National University Corporation Tokyo Medical And Dental University Peptide which can induce antibody capable of recognizing stereostructure of hiv
ES2667425T3 (es) 2011-06-10 2018-05-10 Oregon Health & Science University Glucoproteínas y vectores recombinantes de CMV
EP2568289A3 (en) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
EP2848937A1 (en) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Methods of identifying novel HIV-1 immunogens
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
EP3069730A3 (en) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
CN108997482A (zh) * 2018-08-09 2018-12-14 东莞市朋志生物科技有限公司 用于检测hiv-1的合成肽
WO2022152939A1 (en) 2021-01-18 2022-07-21 Conserv Bioscience Limited Coronavirus immunogenic compositions, methods and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5528933A (en) * 1978-08-21 1980-02-29 Dai Ichi Seiyaku Co Ltd Muramyldipeptide dimer
CA1341482C (en) * 1984-10-31 2005-05-10 Paul A. Luciw Process for preparing fragments of aids-associated retroviruses
US4946945A (en) * 1987-06-23 1990-08-07 Allergy Immuno Technologies, Inc. Immunotherapy agents for treatment of IgE mediated allergies
US5128319A (en) * 1987-08-28 1992-07-07 Board Of Regents, The University Of Texas System Prophylaxis and therapy of acquired immunodeficiency syndrome
CA2025634A1 (en) * 1989-09-19 1991-03-20 Thomas Fuerst Peptides including ctl epitopes of hiv proteins and use thereof
US6565842B1 (en) 1995-06-07 2003-05-20 American Bioscience, Inc. Crosslinkable polypeptide compositions
JP2001502315A (ja) * 1996-10-10 2001-02-20 プローブ・インターナショナル ウイルス感染を処置するための組成物および方法

Also Published As

Publication number Publication date
KR100667121B1 (ko) 2007-01-12
MXPA02010374A (es) 2003-04-25
CA2268372C (en) 2012-11-27
AU732809B2 (en) 2001-05-03
US6670181B2 (en) 2003-12-30
KR100547049B1 (ko) 2006-02-01
US8110203B2 (en) 2012-02-07
CA2268372A1 (en) 1998-04-16
JP2009080118A (ja) 2009-04-16
AU4813197A (en) 1998-05-05
NZ334941A (en) 2000-11-24
CN1327896C (zh) 2007-07-25
US6043347A (en) 2000-03-28
KR20000048994A (ko) 2000-07-25
US20070154917A1 (en) 2007-07-05
US6258599B1 (en) 2001-07-10
WO1998015658A1 (en) 1998-04-16
CN1234078A (zh) 1999-11-03
EP0939835A1 (en) 1999-09-08
HK1023371A1 (en) 2000-09-08
US6335017B1 (en) 2002-01-01
KR20060041157A (ko) 2006-05-11
US20020086034A1 (en) 2002-07-04
JP2001502315A (ja) 2001-02-20
EP0939835A4 (en) 2004-10-27
US20040141996A1 (en) 2004-07-22

Similar Documents

Publication Publication Date Title
BR9712289A (pt) Composições e métodos para o tratamento de infecções virais
ES2087156T3 (es) Metodos para la inactivacion de virus en composiciones farmaceuticas contaminadas por virus.
PT726758E (pt) Peptidos para induzir respostas de linfocitos t citotoxicos ao virus da hepatite b
BR9810745A (pt) Derivados de benzimidazol
CY1106152T1 (el) Νεα ανοσογονα αντι-hiv (ανατοξινες), μεθοδοι παρασκευης και εφαρμογη στην προληψη και στην αγωγη του aids
TNSN91029A1 (fr) Les analogues du nucleoside de 1,3-oxathiolane
ATE362379T1 (de) Induktion rev- und tat-spezifischer zytotoxischer t-zellen zur prävention und behandlung einer infektion durch humanen immundefizienz-virus (hiv)
ES2107459T3 (es) Mejora de la regulacion represora de enfermedades autoinmunes por administracion oral o enteral de autoantigenos.
Archibald et al. Secretory IgA antibodies to human immunodeficiency virus in the parotid saliva of patients with AIDS and AIDS-related complex
BR9714349A (pt) L-nucleosìdeos purina, seus análogos e utilizacões dos mesmos
DE59003895D1 (de) Arbeitszange.
RU94002475A (ru) Фармацевтическая композиция и ее применение для лечения вирусных инфекций
EP1375511A3 (en) Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus
PT534618E (pt) Peptidos para inducao de respostas de linfocitos t citotoxicos ao virus da hepatite b
EP0355825A3 (en) Viral treatment system
DK416089A (da) Heparinfragmenter og -fraktioner med anti-hiv virkning
ATE189394T1 (de) Methode zur behandlung von viralen infektionen
SE9202968D0 (sv) New peptides, diagnostic antigens, use thereof, vaccines and medicaments
BR9916893A (pt) Tratamento
ATE406178T1 (de) Verhinderung von immunreaktivität durch verarmung oder inhibition von antigen-präsentierenden zellen
ATE142262T1 (de) Gegen das menschliche immunschwäche-virus gerichtetes immunpräparat
DK0821593T3 (da) Konjugat af et aktivt middel, et protein og eventuelt et for kroppen ikke som fremmed anset nativt protein
DK0653939T3 (da) Anvendelse af en Hymenoptera-gift til fremstilling af et medikament til behandling af DNA-virusinfektioner
BR9710206A (pt) Uso de um agente de interleucina-8 e formulação farmacéutica antiviral
Nasiri et al. Anti-fungal effect of saliva on black fungus

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: DE ACORDO COM O ART. 37, INDEFIRO DO PRESENTE PEDIDO, UMA VEZ QUE A MATERIA PRETENDIDA NAO ATENDE AO REQUISITO DE ATIVIDADE INVENTIVA ( ART. 8O COMBINADO COM O ART. 13 DA LPI), NOVIDADE ( ART. 8O COMBINADO COM O ART. 11 DA LPI) E QUE AS REIVINDICACOES ESTAO INDEFINIDAS E/OU NAO ESTAO FUNDAMENTADAS NO RELATORIO DESCRITIVO (ART. 25 DA LPI) E QUE OS PEPTIDEOS SINTETICOS COM CORRESPONDENTES NATURAIS NAO SAO CONSIDERADOS INVENCAO, UMA VEZ QUE INCIDEM NO ART. 10 DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.